TiNivo研究:替沃扎尼联合纳武利尤单抗治疗转移性肾细胞癌的安全性与疗效
TiNivo是一项Ib/II期研究,评估替沃扎尼联合纳武利尤单抗治疗转移性肾细胞癌。25例患者接受替沃扎尼1.5 mg每日一次联合纳武利尤单抗240 mg每2周,客观缓解率56%,疾病控制率96%,中位无进展生存期18.9个月,安全性总体可耐受。
要点
- 替沃扎尼1.5 mg联合纳武利尤单抗的客观缓解率为56%,疾病控制率96%。
- 中位无进展生存期18.9个月(95%CI 16.4-未达到),初治与经治患者相似。
- 治疗相关3/4级不良事件发生率80%,32%患者因不良事件停药。
核心结论
- 替沃扎尼联合纳武利尤单抗显示出总体可耐受的不良事件特征和有前景的抗肿瘤疗效。
- 结果支持进一步开发该联合方案用于初治或经治的转移性肾细胞癌患者。
研究设计与样本
- Ib/II期研究,Ib期确定最大耐受剂量为替沃扎尼1.5 mg每日一次,II期在该剂量下额外入组22例。
- 共25例转移性肾细胞癌患者接受替沃扎尼1.5 mg每日一次(服21天停7天)联合纳武利尤单抗240 mg每2周,其中12例(48%)初治、13例(52%)经治。
主要发现
- 治疗相关3/4级不良事件见于20例(80%),4例(17%)因不良事件减量,8例(32%)因不良事件停药。
- 客观缓解率56%(含1例完全缓解),疾病控制率96%,至最佳缓解中位时间7.9周,20例(80%)肿瘤缩小。
- 中位随访19.0个月(范围12.6-22.8),全组中位无进展生存期18.9个月(95%CI 16.4-未达到),初治与经治患者相似。
临床怎么用
- 该联合方案可作为初治或经治转移性肾细胞癌的潜在治疗选择,但需关注3/4级不良事件及停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment with tivozanib, a highly selective and potent vascular endothelial growth factor receptor tyrosine kinase inhibitor, has demonstrated single-agent efficacy in advanced renal cell carcinoma (RCC) along with minimal off-target toxicities and a favorable adverse event (AE) profile. We report final results from TiNivo, a phase Ib/II study of tivozanib combined with nivolumab. PATIENTS AND METHODS: In phase Ib, patients with metastatic RCC received tivozanib 1.0 mg once daily (QD) for 21 days followed by 7 days off treatment (n = 3) or tivozanib 1.5 mg QD (n = 3) plus nivolumab 240 mg every 2 weeks. The maximum tolerated dose was determined to be tivozanib 1.5 mg, and 22 additional patients were enrolled at the maximum tolerated dose for phase II. Primary end points included safety and tolerability, with secondary end points of objective response rate, disease control rate, and progression-free survival. RESULTS: In total, 25 patients were treated with tivozanib 1.5 mg QD [12 (48%) treatment-naïve; 13 (52%) previously treated]. Treatment-related grade 3/4 AEs were reported in 20 patients (80%); 4 patients (17%) experienced AEs that led to dose reduction, and 8 (32%) discontinued due to AEs. The objective response rate was 56% (including one complete response) and disease control rate was 96%, with a median time to best response of 7.9 weeks. Twenty patients (80%) had tumor shrinkage. With a median follow-up of 19.0 months (range, 12.6-22.8), median progression-free survival was 18.9 months (95% confidence interval 16.4-not reached) in all patients and was similar in treatment-naïve and previously treated patients. CONCLUSIONS: Tivozanib plus nivolumab combination therapy showed a generally tolerable AE profile and promising antitumor efficacy. These results support further development of tivozanib combined with nivolumab as a treatment option in patients with treatment-naïve or previously treated metastatic RCC. CLINICAL TRIAL NUMBER: NCT03136627.
引用
- Albiges L, Barthélémy P, Gross-Goupil M, et al. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2020. PMID: 33010459. doi:10.1016/j.annonc.2020.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。